Literature DB >> 1732055

The effect of dietary fat on the rapid development of mammary tumors induced by 7,12-dimethylbenz(a)anthracene in SENCAR mice.

S M Fischer1, C J Conti, M Locniskar, M A Belury, R E Maldve, M L Lee, J Leyton, T J Slaga, D H Bechtel.   

Abstract

We recently reported (J. Leyton et al., Cancer Res., 51: 907-915, 1991) an inverse correlation between skin tumor number and level of dietary linoleic acid (LA) in SENCAR mice following an initiation-promotion protocol. These results differed from the reported (C. Ip et al., Cancer Res., 45: 1997-2001, 1985) positive correlation between dietary LA and tumor incidence for the rat mammary gland. The goal of the study reported here was to determine whether this dissimilarity was due to organ site or species differences. Female SENCAR mice were fed 1 of 3 15% fat diets containing LA at levels of 0.8, 4.5, and 8.4% before, during, and after intragastric administration of 6 mg (1 mg/week) 7,12-dimethylbenz(a)anthracene. A positive correlation between level of dietary LA and mammary tumor incidence was observed such that for the first 15 weeks, the incidence was greatest in the 8.4% LA diet group, followed by the 4.5% and then the 0.8% LA groups. Distinct dietary effects on latency were also noted in that 15, 12, and 8 weeks after cessation of 7,12-dimethylbenz(a)anthracene were required for a 40% carcinoma incidence in the 0.8, 4.5, and 8.4% LA diet groups, respectively. A histopathological analysis of all tumors revealed that the predominant type was the adenosquamous carcinoma, which comprised 46.6, 54.1, and 77.7% of all mammary tumors for diets containing 0.8, 4.5, and 8.4% LA, respectively. The second most common tumor was the adenocarcinoma type B, which was found with a frequency of 33% in the 0.8% and 4.5% LA diet groups and 22% in the 8.4% LA diet group. These results indicate that SENCAR mice have a short latency period for 7,12-dimethylbenz(a)anthracene-induced mammary tumor development and that rat and mouse mammary tumor development is modified by dietary LA in a similar manner, although in the SENCAR mouse dietary LA did not have a saturating effect. In addition, high dietary LA was found to be associated specifically with an increased incidence of adenosquamous carcinomas but not of other types of mammary tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732055

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review.

Authors:  Laura B Samuelsson; Dana H Bovbjerg; Kathryn A Roecklein; Martica H Hall
Journal:  Neurosci Biobehav Rev       Date:  2017-10-13       Impact factor: 8.989

2.  Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein.

Authors:  Tai L Guo; Rui P Chi; Denise M Hernandez; Wimolnut Auttachoat; Jian F Zheng
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

3.  Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.

Authors:  Sharad S Singhal; David Horne; Jyotsana Singhal; Steven Vonderfecht; Ravi Salgia; Sanjay Awasthi
Journal:  Mol Carcinog       Date:  2019-04-21       Impact factor: 4.784

Review 4.  Large Animal Models of Breast Cancer.

Authors:  Pinaki Mondal; Katie L Bailey; Sara B Cartwright; Vimla Band; Mark A Carlson
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

5.  Carcinogenic effects in a phenylketonuria mouse model.

Authors:  Neil Sidell; Lijuan Hao; Marzia Pasquali; J David McDonald
Journal:  PLoS One       Date:  2009-01-27       Impact factor: 3.240

6.  Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice.

Authors:  Rafat A Siddiqui; Kevin A Harvey; Candace Walker; Jeffrey Altenburg; Zhidong Xu; Colin Terry; Ignacio Camarillo; Yava Jones-Hall; Cary Mariash
Journal:  BMC Cancer       Date:  2013-09-13       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.